Annual report pursuant to Section 13 and 15(d)

Net Loss Per Share

v3.19.1
Net Loss Per Share
12 Months Ended
Dec. 31, 2018
Earnings Per Share [Abstract]  
Schedule of Net Loss Per Share

14.

Net Loss Per Share


Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the periods. Fully diluted net loss per common share is computed using the weighted average number of common and dilutive common equivalent shares outstanding during the periods. Common equivalent shares consist of stock options and warrants that are computed using the treasury stock method.


For the years ended December 31, 2018 and 2017, all of the Company’s common stock options, unvested restricted stock units and warrants are anti-dilutive and therefore have been excluded from the diluted calculation.


The following table reconciles net loss to net loss attributable to Heat Biologics, Inc.:


 

 

For the years ended

December 31,

 

 

 

2018

 

2017

 

Net loss

 

$

(16,591,293

)

$

(12,409,866

)

Net loss - Non-controlling interest

 

 

(857,439

)

 

(568,195

)

Net loss attributable to Heat Biologics, Inc.

 

$

(15,733,854

)

$

(11,841,671

)

 

 

 

 

 

 

 

  

Weighted-average number of common shares used in net loss per share attributable to common stockholders —basic and diluted

 

 

17,485,461

 

 

3,845,342

 

Net loss per share attributable to Heat Biologics, Inc —basic and diluted

 

$

(0.90

)

$

(3.08

)


The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:


 

 

 

For the years ended

December 31,

 

 

 

 

2018

 

2017

 

Outstanding stock options

 

 

 

465,303

 

 

266,810

 

Unvested restricted stock units

 

 

 

56,520

 

 

21,779

 

Outstanding common stock warrants

 

 

 

9,030,730

 

 

310,397